Investigational drug · Phase 2
BPI-361175
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-small Cell Lung Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 7, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BPI-361175"
First trial start
2026
Jul 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BPI-361175", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Carcinoma
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BPI-361175" as an intervention, largest first.
Betta Pharmaceuticals Co., Ltd.Industry
NCT05329298 · 90 participants (planned) · Start Jul 21, 2021 · Primary completion Jun 30, 2023
Drug: BPI-361175 · For: Non-small Cell Lung Cancer
Sites: Zhengzhou, China; Wuhan, China; Changsha, China · 8 sites in all
Xcovery Holdings, Inc.Industry
NCT05393466 · 30 participants (planned) · Start Jul 1, 2026 · Primary completion Jan 30, 2028
Drug: BPI-361175 · For: Non-small Cell Lung Carcinoma
Newest research
PubMed records naming it or its code names, newest first.
- Recent advances in synthetic strategies of fourth-generation EGFR tyrosine kinase inhibitors under clinical trials for the treatment of resistant non-small cell lung cancer (NSCLC).
Kadam VM, Patel HM · Bioorg Chem 2026
- A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Gawli CS, Patil CR, Patel HM · Bioorg Med Chem 2025
Also in development for Non-small Cell Lung Carcinoma
- FurmonertinibPhase 38 trials
Allist Pharmaceuticals, Inc. · Non-Small Cell Lung Cancer, NSCLC, NSCLC Patients With Brain Metastasis
- PF-08046054SGN-PDL1VPhase 32 trials
Pfizer · Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.